Solutions
- Tumor sensitization & immune cell killing
- Tumor antigen-specific T cell killing
- Translational Research
- TLS-GC reaction
- TLS Detection & Scoring for Cancer Immunotherapy
- TLS Detection and Scoring by Digital Pathology
- Target identification & validation for cancer immunotherapies
- T cell activation & immune checkpoint inhibition
- Syngeneic Tumor Models for the In Vivo Assessment Cancer Immunotherapies
- RNA Sequencing
- Renal Cancer
- Immune Response Profiling for Cancer Immunotherapies - Preclinical CRO Services
- Proteomics
- Mixed Lymphocyte Reaction (MLR)
- Sarcoma
- Colon cancer
- Macrophage assays
- In Vivo Models Of PD-1/PD-L1 Axis Blockade
- In Vivo Models Of CTLA-4 Blockade
- In Vivo Models
- In Vivo immunization tumor models
- Immune cell tumor killing
- Immune cell migration
- Immune cell-mediated tumor killing assays
- Immune cell activation
- Glioma
- Flow cytometry
- Triple Negative Breast Cancer
- Spatial transcriptomics
- Quantitative digital pathology
- Cytokine Release Syndrome
- Colon Cancer
- Cell-based Assays
- Biomarker Discovery & Testing for Immuno-Oncology
- Antibody-dependent cell cytotoxicity (ADCC)
- Breast Cancer
News
- Category: Events
- Explicyte will be attending the AACR Annual Meeting 2019 in Atlanta
- Explicyte intensifies its efforts in translational research & will attend the next ASCO Annual Meeting
- Explicyte posters presented at the AACR Virtual Annual Meeting 2020
- In vivo syngeneic tumor models for novel drug assessment and MoA deciphering in a cost-saving way
- Explicyte will be attending the ESMO Immuno-Oncology Congress In Geneva
- New in vivo shuttle session: syngeneic mouse tumor models for novel drug assessment and MoA deciphering
- Deciphering anti-PDL1 effect in a syngeneic mouse model of sarcoma
- Anti-angiogenic therapy combination with hypoxia-regulating agent leads to improved tumor regression
- AACR Virtual Annual Meeting 2020… Discover our collaborative poster with Domain Therapeutics
- Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
- We’ll be there! Meet Explicyte at AACR event in New Orleans
- Digital Spatial Profiling to reveal mechanisms of response to cancer immunotherapies
- Gearing up for ASCO 2022 event! Meet Explicyte in Chicago!
- Summer is here, catch up on our latest top highlights!
- Meet Explicyte! Join us at The 37th annual SITC event in Boston
- While awaiting the 2023 new year, have an overview on some of our 2022 highlights!
- Explicyte to present three posters at the AACR Annual Meeting 2023
- Back from ASCO: Interview with Alban Bessede
- Meet us a the SITC in Houston in November
- Ultra-trail: 330 km in the Alpes to support cancer immunotherapy research
- Webinar on TLS modulation September 5th !
- Meet our CSO at the AACR IO 2025 in February
- Category: Jobs
- Category: Press releases
- Eurostars Granted Project. A Novel Modified Natural Killer (NK) Cell Immunotherapy For The Treatment Of Solid Tumours
- Explicyte and Institut Bergonié partner for comprehensive translational research programs in immuno-oncology
- Explicyte and Institut Bergonié associate in a clinical trial report publication
- CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10M in the fifth RHU call
- A partnership between Explicyte and Bergonié Institute fuels major breakthroughs
- New avenues in cancer immunotherapy. A conversation with Pr. Italiano
- Category: Publications & posters
- IDO targeting in sarcoma: biological and clinical implications
- Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE)
- Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker
- Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1
- CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
- Discover our latest TRAMUNE study
- Our latest REGOMUNE study is just published!
- Targeting tryptophan catabolism in the era of cancer immunotherapy: challenges and perspectives
- Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer
- New paper in Nature Medicine about Tertiary Lymphoid Structures (TLS) and immune checkpoint inhibition in patients with advanced soft-tissue sarcoma
- A new collaborative work reported in Annals of Oncology and featured at ASCO 2022!
- Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy
- Discover our latest study, a novel gut-restricted small molecule agonist enhances immune checkpoint inhibitor efficacy
- Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors
- Results from the PEMBROSARC basket study
- Randomized phase 2 trial of oncolytic virus in patients with soft-tissue sarcoma
- Phase 2 trial of intravenous oncolytic virus JX-594 in patients with breast cancer
- Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers
- New paper in Clinical Cancer Research : Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures
- TROP2 – a strong predictor of resistance to immunotherapy in lung cancer
- Our latest abstract at ASCO 2024 about anti-VEGFR therapy combined with immune checkpoint blockade
- New paper : Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors
- From “cold” to “hot” soft-tissue sarcomas – focus on a key 2024 paper for the Sarcoma Awareness Month
- New Paper in Molecular Cancer! Spatial Transcriptomics & Plasma Proteomics Unveil Mechanisms of Resistance to PD-1/PD-L1 + Angiogenesis Inhibition in Gastric Cancers
- New paper in the Journal of Hematology & Oncology ! Tumor microenvironment predicts response of soft tissue sarcoma patients to neoadjuvant chemotherapy
- New Paper in Cell Reports Medicine: A 25-Gene Signature of T Cell Exhaustion Predicts Immunotherapy Response in Lung Adenocarcinoma
- Category: Scientific contents
- IDO1 Expression Does Not Strictly Match L-Kynurenine Production In Cancer Tissues
- Preclinical Mouse Tumor Models Of Immune Checkpoint Inhibition
- Launch Of Explicyte Immuno-Oncology!
- Functional Effect Of PDL1 Blockade On A Cell-Based Assay
- Orthotopic Mouse Model Of Glioblastoma
- In Vitro Immune Cell-Mediated Killing
- In Vivo Syngeneic Subcutaneous CT26 Colon Tumor Model Shuttle Session
- Orthotopic GL261 Glioma Mouse Model To Test Your Immunomodulatory Compound
- Immunosuppressive Tumor Microenvironment In OT 4T1 Breast Tumor Model
- Combination Of In Vivo Efficacy Monitoring With Intratumoral Biopsy To Assess New Cancer Therapies & Decipher Their MoA
- In Vitro Immune Cell Activation
- New In Vivo Syngeneic Mammary Fat Pad Mouse Model Shuttle Session
- Neutrophil chemotaxis assay for cancer immunotherapy screening
- In vivo syngeneic subcutaneous tumor models for cost-saving efficacy studies
- Intratumoral microdialysis-based approach to assess tumor immunometabolism & specific immunometabolic pathways-targeting
- M2 Macrophage Suppression Assay
- Involvement of CD8 T cells in the tumor growth control and in the response to PD1 and PDL1 antibodies
- Antibody-dependent cell-mediated cytotoxicity (ADCC) assay for in vitro testing
- B cells as key players in shaping anti-tumor immune response
- Cytokine release as a relevant surrogate for the immune cell subset function assessment on an in vitro platform of IO
- Quantitative histology to feature the tumor immune contexture
- Explicyte is proud to be a certified Nanostring partner…Let’s start the Digital Spatial Profiling revolution together!
- Microdialysis For Dynamic Changes Of Target Molecules
- Spotlight on Explicyte integrated histology platform in Nature Cancer!
- A syngeneic Lewis LLC1 mouse model for preclinical immuno-oncology testing of novel anti-cancer strategies
- Spotlight on adenosine-mediated suppression of dendritic cell function
- Spatial transcriptomics reveals key determinants of response to immune checkpoint blockade in NSCLC
- Strenghten your immuno-oncology research with our complete digital pathology capacities
- Spotlight on our in vivo advances
- GeoMx Cancer Transcriptome Atlas (CTA)
- GeoMx Whole Transcriptome Atlas (WTA)
- New! Olink proteomics joins the dance of our biomarker discovery capacities
- Ovarian cancer ascites to improve your translational research & therapeutic testing!
- How to fully exploit the mixed leukocyte reaction assay?
- Benefit from a robust mixed leukocyte reaction assay to evaluate immunomodulatory properties of your candidates
- Macrophage-based assays to assess immunotherapeutics
- A robust mixed leukocyte reaction assay to evaluate immunomodulatory properties of your candidates
- Translational research in cancer immunotherapy: 5 key findings
- First immuno-oncology CRO in Europe equipped with 10x Xenium platform for single-cell spatial transcriptomics
- 3 exclusive slots with the IO panel on the Xenium for Christmas!
- T cell tumor killing assays and more, an update !
- Category: Uncategorised